Summary of Significant Accounting Policies (Tables)

6 Months Ended

Dec. 31, 2016

Summary of Significant Accounting Policies

Schedule of the Company's net sales by medical indication

(In thousands)	For the Three Months Ended December 31,				For the Six Months Ended December 31,
Medical Indication	2016		2015		2016		2015
Antibiotic	$	4,792	$	2,828	$	8,572	$	5,556
Anti Psychosis	15,365		730		32,685		3,472
Cardiovascular	11,975		13,082		24,669		21,385
Central Nervous System	10,555		6,077		20,904		6,077
Gallstone	13,425		18,719		26,308		38,691
Gastrointestinal	18,977		8,617		37,029		8,693
Glaucoma	5,311		6,543		11,095		13,365
Migraine	7,863		5,705		15,023		11,247
Muscle Relaxant	3,004		1,393		6,536		3,054
Obesity	960		851		1,795		1,830
Pain Management	7,439		8,074		14,047		16,207
Respiratory	2,957		1,396		5,170		1,396
Thyroid Deficiency	45,431		37,432		85,269		78,534
Urinary	4,693		3,378		9,794		3,593
Other	10,173		9,963		20,519		18,121
Contract manufacturing revenue	8,024		2,271		13,088		2,271
Total	$	170,944	$	127,059	$	332,503	$	233,492

Summary of products which accounted for at least 10% of net sales

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2016		2015		2016		2015
Product 1	27	%	29	%	26	%	34	%
Product 2	8	%	15	%	8	%	17	%

Summary of customers which accounted for at least 10% of net sales

	For the Three Months Ended December 31,				For the Six Months Ended December 31,
	2016		2015		2016		2015
Customer A	28	%	27	%	28	%	27	%
Customer B	20	%	18	%	20	%	15	%